#### 

Applicant Name:

#### **Attachment A**

**NCI requires an explanation of the cancer relevancy of your work. Provide specific examples of how your work is relevant to the prevention, diagnosis, treatment or investigation of cancer.**

**Planned Cancer Research Interactions/Collaborations:**

Attachment B

UNIVERSITY OF MARYLAND PROGRAM IN ONCOLOGY

REQUEST FOR APPOINTMENT IN THE UNIVERSITY OF MARYLAND

PROGRAM IN ONCOLOGY

I hereby request membership/associate membership in the University of Maryland Program in Oncology. I understand and accept the following obligations that such an appointment confers:

1. Support the basic concept, mission, and goals of the Marlene and Stewart Greenebaum Comprehensive Cancer Center.
2. Participate fully in respective research programs, collaborative efforts, and communications about research and patient care initiatives.
3. Provide the Cancer Center with the information necessary to maintain current data about scientific activity and grant support in order to maintain the Center’s database on oncology-related activities.
4. Request funds in grant applications to support the UMGCCC Shared Services provided to all investigators by the Cancer Center.
5. Attend cancer seminars and program meetings in areas of interest.
6. Report all funded activities to the Cancer Center at the time membership is granted, and as requested by the Director.
7. Include recognition of membership in the Program in Oncology and the Cancer Center on all cancer-related academic papers, grants, journal articles, poster sessions, and/or abstracts.
8. Participate in cancer-related educational activities (both medical and graduate school) sponsored by the Cancer Center.
9. Participate in the Cancer Center core grant program project and training application process as requested.
10. Participate in seminars, conferences, and UMGCCC committees.

Applicant Name (please print): \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

Applicant Signature: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

Concurrence: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

##### Department Chair

# **Attachment C**

# **Applicant Name:** \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_­­\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

**UMMS Institution:** \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

**University of Maryland Campus:** \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

**Academic Department:** \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

**Location of principle clinical practice:** \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

**Work Address:** \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

**Email:** \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

**Phone:** \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

**Gender:** Male Female

**Race:** African American Other Pacific Islander

Asian White

American Indian Indian

Not Listed

**Ethnicity:** Hispanic or Latino Not Hispanic or Latino

# **Program in Oncology Research Programs**

***Please indicate your primary (1) and secondary (2) interest by program.***

## Experimental Therapeutics Program

*Contact: Maria Baer, M.D., Professor, Department of**Medicine*

*Feyruz Rassool, Ph.D., Professor, Department of Radiation Oncology*

**Program Description:**

The overarching goal of the Experimental Therapeutics (ET) Program of UMGCCC is to develop and test new therapies for solid tumors and hematologic malignancies based on innovative preclinical research. The emphasis is on bringing basic and preclinical discoveries from ET members to early-stage clinical testing and also on providing platforms for investigators in other programs to study their findings in the clinical setting. To achieve this mission, the program focuses on three specific themes and related aims:Theme 1: Molecular targets—develop and test new cancer therapies based on novel molecular targets; Theme 2: Treatment delivery—develop and test novel formulations and delivery strategies for cancer treatments and new regional therapies; and Theme 3: Radiation—develop and test novel strategies for utilizing ionizing and nonionizing radiation and for radiation sensitization and protection in the multimodality management of cancers.

## Tumor Immunology and Immunotherapy Program

## *Contact: Xuefang Cao, Ph.D., Associate Professor, Microbiology & Immunology*

*Aaron Rapoport, M.D., Professor, Department of**Medicine*

**Program Description:**The principal scientific goals of the Program are to develop, characterize, and implement immunological approaches for the prevention, treatment and monitoring of cancer and cancer progression.  To achieve this goal, the program focuses on enhancing adaptive and innate antitumor responses and mitigating immunoinhibitory signals. The TII Program’s research and clinical endeavors focus on the following themes: (1) Cell-based cancer immunotherapies— Develop novel approaches to elicit active tumor immunity capable of reducing or preventing malignant cell growth, (2) Inhibiting immunosuppression—Develop strategies to overcome tumor immune evasion including the blocking of negative signals received by T cells and impeding the activity of suppressive cell types, and (3) Cancer and inflammation—Elucidate the roles and associations between infection, inflammatory responses and cancer development including the generation of an immunosuppressive tumor microenvironment.

## Hormone Responsive Cancers Program

### Contact: Stuart S. Martin, Ph.D., Professor, Department of Physiology

*Arif Hussain, M.D., Professor, Department of Medicine*

**Program Description:**

The overarching goal of the Hormone Responsive Cancers (HRC) Program of UMGCCC is to reduce morbidity and mortality from cancers of hormone-responsive tissues. To achieve this mission, the program focuses on three specific themes and related aims: Theme 1: Therapeutic strategies against hormone-responsive tumors—identify new agents to target malignancies that remain responsive to hormone manipulation; Theme 2: Mechanisms of innate and acquired hormone resistance—identify and target the mechanisms that confer de novo or acquired resistance to hormone manipulation; and Theme 3: Invasion and metastasis—identify the mechanisms that promote tumor dissemination and identify therapeutic strategies to target these mechanisms.

# **Molecular and Structural Biology Program**

*Contact: David J. Weber, Ph.D., Professor, Department of Biochemistry & Molecular Biology*

*France Carrier, Ph.D., Professor, Department of Radiation Oncology*

**Program Description**:

The overall goal of the MSB Program is to elucidate molecular mechanisms and cellular processes that are altered in cancer and translate these findings towards treating cancer.  The research interests of the Program members can be divided into three broad themes including:  (1) DNA damage, repair, and genomic instability and to characterize how defects in DNA repair lead to genomic instability and carcinogenesis; (2) Dysregulation of transcriptional & posttranscriptional control and to determine how defects in gene expression processes lead to dysregulation of protein expression in cancer; (3) Cancer cell signaling and to delineate how signaling pathways are dysregulated in cancer.  There is also an effort to identify specific biomolecules that can be targeted for suppressing cancer.  In this regard, the basic science coming from MSB members laboratories are evaluated for their potential as therapeutic targets and structure-based drug design approaches are used to develop small molecules and/or biologics that will serve as leads for the development of novel therapeutic agents.

**Population Science Program:**

*Contact:* *Joanne F. Dorgan, Ph.D., M.P.H. Professor, Department of Epidemiology and Public Health*

*Cheryl L. Knott, Ph.D., Professor, Department of Behavioral and Community Health*

**Program Description:**The overall goals of the Population Science (PS) Program are to identify determinants of cancer etiology, cancer-related behaviors, and survivorship and to translate basic discoveries into behavioral cancer prevention and control interventions. To achieve these goals, research addresses four themes: 1) epidemiology of infection- and hormone-related cancers; 2) tobacco and nicotine; 3) equity in cancer prevention and early detection; and 4) cancer survivorship. The program has unique strengths and a significant emphasis on reducing cancer disparities, working directly with populations in the UMGCCC catchment area.